These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
169 related items for PubMed ID: 8186356
1. Strategies for inhibiting the effects of thrombin. Harker LA. Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356 [Abstract] [Full Text] [Related]
2. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594 [Abstract] [Full Text] [Related]
3. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Proc Natl Acad Sci U S A; 1992 Jul 01; 89(13):6040-4. PubMed ID: 1385867 [Abstract] [Full Text] [Related]
4. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates. Hortin GL, Trimpe BL. J Biol Chem; 1991 Apr 15; 266(11):6866-71. PubMed ID: 1849894 [Abstract] [Full Text] [Related]
5. Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II. Hortin GL, Tollefsen DM, Benutto BM. J Biol Chem; 1989 Aug 25; 264(24):13979-82. PubMed ID: 2760054 [Abstract] [Full Text] [Related]
8. Inhibition of thrombin's clotting activity by synthetic peptide segments of its inhibitors and substrates. Hortin GL, Benutto BM. Biochem Biophys Res Commun; 1990 Jun 15; 169(2):437-42. PubMed ID: 2357214 [Abstract] [Full Text] [Related]
10. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. Thromb Haemost; 1998 Feb 15; 79(2):431-8. PubMed ID: 9493603 [Abstract] [Full Text] [Related]
12. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J. Blood; 1992 Aug 15; 80(4):960-5. PubMed ID: 1498336 [Abstract] [Full Text] [Related]
14. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP, Bernat A, Gaich C, Herbert M. Thromb Haemost; 2002 Feb 15; 87(2):238-44. PubMed ID: 11858483 [Abstract] [Full Text] [Related]
15. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. Church FC, Phillips JE, Woods JL. J Biol Chem; 1991 Jun 25; 266(18):11975-9. PubMed ID: 2050691 [Abstract] [Full Text] [Related]
18. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Linder R, Frebelius S, Jansson K, Swedenborg J. Blood Coagul Fibrinolysis; 2003 Feb 25; 14(2):139-46. PubMed ID: 12632023 [Abstract] [Full Text] [Related]
19. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Fenton JW, Villanueva GB, Ofosu FA, Maraganore JM. Haemostasis; 1991 Feb 25; 21 Suppl 1():27-31. PubMed ID: 1894193 [Abstract] [Full Text] [Related]
20. Comparison of hirudin and hirudin PA C-terminal fragments and related analogs as antithrombin agents. Krstenansky JL, Owen TJ, Yates MT, Mao SJ. Thromb Res; 1988 Oct 15; 52(2):137-41. PubMed ID: 3194888 [Abstract] [Full Text] [Related] Page: [Next] [New Search]